Steady-State Pharmacokinetics of Tacrine in Long-Term Treatment of Alzheimer Patients

The pharmacokinetics of the cholinesterase inhibitor tacrine was studied in 5 Alzheimer patients during 12–31 months of treatment. A mean average steady-state concentration in plasma ranging from 1.1